| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Neurosurgery [H. K., S. I., I. Y., S. F.], Urology [K. K., N. S., M. H., T. S., M. Y.], and Radiology [S. T.], Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236, Japan
Hemangioblastoma is one of the benign tumors in the central nervous system. It is often associated with the von Hippel-Lindau (VHL) disease, a well known hereditary tumor syndrome. It is believed that inactivation of both alleles of VHL tumor suppressor gene is essential in the tumorigenic processes in hemangioblastomas associated with VHL disease. The molecular basis for the development of sporadic hemangioblastomas is not known. Here, we analyzed 13 cases of primary sporadic hemangloblastomas for somatic mutations of VHL gene with single strand conformational polymorphism analyses of the tumor DNAs. We detected abnormal single strand conformational polymorphism pattern in 7 tumors (54%). Of these 7 possibly mutated tumors, we successfully characterized 3 tumors by direct sequencing. We were unable to sequence 4 tumors because of the poor quality of DNA obtained from paraffin blocks. Somatic mutations in the 3 tumors were 2 missense mutations and 1 microdeletion. These mutations were observed in 1 tumor in exon 1 and 2 tumors in exon 2. Our results suggest that mutations of VHL tumor suppressor gene are involved in the development of at least 20% of sporadic central nervous system hemangioblastomas.
1 H. K. and K. K. contributed equally to this work.
2 To whom requests for reprints should be addressed.
Received 7/11/94. Accepted 8/ 3/94.
This article has been cited by other articles:
|
|
 |
|
  T. Schlesinger, B. Appukuttan, T. Hwang, L.-o. Atchaneeyakasul, C.-C. Chan, Z. Zhuang, J. T. Stout, and D. J. Wilson Internal En Bloc Resection and Genetic Analysis of Retinal Capillary Hemangioblastoma Arch Ophthalmol, September 1, 2007; 125(9): 1189 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R Woodward and E. R Maher Von Hippel-Lindau disease and endocrine tumour susceptibility. Endocr. Relat. Cancer, June 1, 2006; 13(2): 415 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Y. Kim and W. G. Kaelin Role of VHL Gene Mutation in Human Cancer J. Clin. Oncol., December 15, 2004; 22(24): 4991 - 5004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Ma, L. Tessarollo, S.-B. Hong, M. Baba, E. Southon, T. C. Back, S. Spence, C. G. Lobe, N. Sharma, G. W. Maher, et al. Hepatic Vascular Tumors, Angiectasis in Multiple Organs, and Impaired Spermatogenesis in Mice with Conditional Inactivation of the VHL Gene Cancer Res., September 1, 2003; 63(17): 5320 - 5328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kanno, I. Yamamoto, M. Yoshida, and H. Kitamura Meningioma showing VHL gene inactivation in a patient with von Hippel-Lindau disease Neurology, April 8, 2003; 60(7): 1197 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J C C Rocha, R L A Silva, B B Mendonca, S Marui, A J G Simpson, and A A Camargo High frequency of novel germline mutations in the VHL gene in the heterogeneous population of Brazil J. Med. Genet., March 1, 2003; 40(3): e31 - 31. [Full Text] [PDF]
|
|
|
|
|
|
H. Murata, N. Tajima, Y. Nagashima, M. Yao, M. Baba, M. Goto, S. Kawamoto, I. Yamamoto, K. Okuda, and H. Kanno Von Hippel-Lindau Tumor Suppressor Protein Transforms Human Neuroblastoma Cells into Functional Neuron-like Cells Cancer Res., December 1, 2002; 62(23): 7004 - 7011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Zatyka, C Morrissey, I Kuzmin, M I Lerman, F Latif, F M Richards, and E R Maher Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter J. Med. Genet., July 1, 2002; 39(7): 463 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Allen, A. R. Webster, R. Sui, J. Brown, C. M. Taylor, and E. M. Stone Molecular Characterization and Ophthalmic Investigation of a Large Family With Type 2A von Hippel-Lindau Disease Arch Ophthalmol, November 1, 2001; 119(11): 1659 - 1665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yang and W. G. Kaelin Jr. Molecular Pathogenesis of the Von Hippel-Lindau Hereditary Cancer Syndrome: Implications for Oxygen Sensing Cell Growth Differ., September 1, 2001; 12(9): 447 - 455. [Full Text] [PDF]
|
|
|
|
|
|
M. S. Wiesener, P. M. Munchenhagen, I. Berger, N. V. Morgan, J. Roigas, A. Schwiertz, J. S. Jurgensen, G. Gruber, P. H. Maxwell, S. A. Loning, et al. Constitutive Activation of Hypoxia-inducible Genes Related to Overexpression of Hypoxia-inducible Factor-1{{alpha}} in Clear Cell Renal Carcinomas Cancer Res., July 1, 2001; 61(13): 5215 - 5222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Glasker, B U Bender, T W Apel, V van Velthoven, L M Mulligan, J Zentner, and H P H Neumann Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system J. Neurol. Neurosurg. Psychiatry, May 1, 2001; 70(5): 644 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kamada, K. Suzuki, Y. Kato, H. Okuda, and T. Shuin von Hippel-Lindau Protein Promotes the Assembly of Actin and Vinculin and Inhibits Cell Motility Cancer Res., May 1, 2001; 61(10): 4184 - 4189. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. U. Bender, M. Gutsche, S. Gläsker, B. Müller, G. Kirste, C. Eng, and H. P. H. Neumann Differential Genetic Alterations in von Hippel-Lindau Syndrome-Associated and Sporadic Pheochromocytomas J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4568 - 4574. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. L. Semenza HIF-1 and human disease: one highly involved factor Genes & Dev., August 15, 2000; 14(16): 1983 - 1991. [Full Text]
|
|
|
|
 |
|
 A. R. Schoenfeld, E. J. Davidowitz, and R. D. Burk Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products PNAS, July 18, 2000; 97(15): 8507 - 8512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kanno, F. Saljooque, I. Yamamoto, S. Hattori, M. Yao, T. Shuin, and H.-S. U Role of the von Hippel-Lindau Tumor Suppressor Protein during Neuronal Differentiation Cancer Res., June 1, 2000; 60(11): 2820 - 2824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Los, S. Zeamari, J. A. Foekens, M. F. B. G. Gebbink, and E. E. Voest Regulation of the Urokinase-type Plasminogen Activator System by the von Hippel-Lindau Tumor Suppressor Gene Cancer Res., September 1, 1999; 59(17): 4440 - 4445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kawahara, H. Kume, K. Ueki, K. Mishima, T. Sasaki, and T. Kirino VHL gene inactivation in an endolymphatic sac tumor associated with von Hippel- Lindau disease Neurology, July 1, 1999; 53(1): 208 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-C. Chan, A. O. Vortmeyer, E. Y. Chew, W. R. Green, D. M. Matteson, D. F. Shen, W. M. Linehan, I. A. Lubensky, and Z. Zhuang VHL Gene Deletion and Enhanced VEGF Gene Expression Detected in the Stromal Cells of Retinal Angioma Arch Ophthalmol, May 1, 1999; 117(5): 625 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Krieg, H. H. Marti, and K. H. Plate Coexpression of Erythropoietin and Vascular Endothelial Growth Factor in Nervous System Tumors Associated With von Hippel-Lindau Tumor Suppressor Gene Loss of Function Blood, November 1, 1998; 92(9): 3388 - 3393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Iliopoulos, M. Ohh, and W. G. Kaelin Jr. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation PNAS, September 29, 1998; 95(20): 11661 - 11666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Lonergan, O. Iliopoulos, M. Ohh, T. Kamura, R. C. Conaway, J. W. Conaway, and W. G. Kaelin Jr. Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2 Mol. Cell. Biol., February 1, 1998; 18(2): 732 - 741. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Walker Molecular Genetics of Renal Carcinogenesis Toxicol Pathol, January 1, 1998; 26(1): 113 - 120. [Abstract] [PDF]
|
|
|
|
 |
|
 T. J. Manski, D. K. Heffner, G. M. Glenn, N. J. Patronas, A. T. Pikus, D. Katz, R. Lebovics, K. Sledjeski, P. L. Choyke, B. Zbar, et al. Endolymphatic Sac Tumors: A Source of Morbid Hearing Loss in von Hippel-Lindau Disease JAMA, May 14, 1997; 277(18): 1461 - 1466. [Abstract] [PDF]
|
|
|
|
 |
|
 A Kibel, O Iliopoulos, J. DeCaprio, and W. Kaelin Jr Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C Science, September 8, 1995; 269(5229): 1444 - 1446. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
